Depo-Provera Lawsuit Update: Settlement, Payouts & Deadlines

What Is a Depo Shot Settlement?

A Depo shot settlement is money paid to women who developed a meningioma — a tumor in the tissue that covers the brain or spinal cord — after using Depo-Provera for an extended period. The lawsuits claim Pfizer knew about the tumor risk and didn’t warn U.S. patients in time.

Depo-Provera is a birth control shot. A doctor gives it every three months. The active ingredient is medroxyprogesterone acetate, a synthetic hormone. Millions of American women have used it since the FDA approved it for contraception in 1992. You can see the current FDA prescribing information (December 2025 revision).

Two companies are named as defendants: Pfizer Inc. and Pharmacia & Upjohn Co. LLC, the original patent holder that Pfizer later acquired. Early in the case, three companies that distribute the generic version — Prasco LLC, Greenstone LLC, and Viatris Inc. — were also named. Courts later dismissed them.

Here’s why that matters if you used the generic version. Under Supreme Court rulings in PLIVA, Inc. v. Mensing (2011) and Mutual Pharmaceutical Co. v. Bartlett (2013), generic drug distributors generally can’t be sued for failing to change a warning label. Federal law requires their label to match the brand name’s label exactly. They’re not legally allowed to add a warning on their own, so courts have ruled they can’t be held liable for not adding one.

Say you got the shot from a generic supplier and never even saw the brand name Depo-Provera on your chart. Does that change anything for you? No. The active ingredient and the alleged risk are identical. Your claim isn’t weaker just because a pharmacy filled it with a generic — you just pursue it against Pfizer and Pharmacia & Upjohn instead of the generic distributor.

A lot of women genuinely don’t know which version they got. Pharmacies and clinics can substitute a generic without always mentioning it, especially years after the fact. That’s a real, common gap in people’s memory — not a reason to assume you don’t qualify. An attorney can usually pull your pharmacy and clinic records to sort out which product you actually received.

How Much Are Depo-Provera Settlements Worth?

There’s no official payout amount yet. The settlement terms haven’t been made public. Attorneys estimate individual Depo-Provera settlement amounts could range from $75,000 to $1.5 million or more, depending on tumor severity, treatment required, and how strong the medical evidence is. Treat any specific number you see online as an estimate, not a promise.

Here’s why no number exists yet. In June 2026, Pfizer and the lawyers leading the case announced a settlement “in principle.” That’s a handshake agreement on the big picture — Pfizer agrees to pay, and both sides agree on a general framework. It is not the same as a finalized deal. In July 2026, the parties signed a formal Master Settlement Agreement, which locks in more detail. But the actual dollar figures for individual cases — the compensation grid — still hasn’t been released publicly as of this writing.

You’ll see different ranges on different law firm websites. That’s not because someone got it wrong. Firms build these estimates by comparing Depo-Provera to other drug lawsuits that have already settled, like Zantac and Essure, and to typical meningioma injury verdicts in general. Different comparison cases produce different ranges. None of them are official until the court-approved numbers come out.

For a sense of scale, a 2021 Canadian class action over Depo-Provera and bone density loss — a different, unrelated set of claims — settled for around $2 million total across all claimants. That’s a much smaller case than the current U.S. meningioma litigation, but it shows Pfizer has settled Depo-Provera claims before.

Average Depo Settlement Amounts

Comparable meningioma lawsuits — not specific to Depo-Provera — have settled for an average of about $868,000, with jury verdicts averaging closer to $3 million, based on figures drawn from meningioma injury litigation tracked by the National Library of Medicine. These are reference points from similar cases, not confirmed Depo-Provera numbers.

Most mass tort settlements — and this one will likely be no different — use a tiered compensation structure instead of one flat number for everyone. Cases with the most severe, permanent injuries land in the top tier and get the largest payments. Cases with mild or resolved injuries land in a lower tier.

Consider two women who both used Depo-Provera for three years. One had a meningioma removed with surgery and now has permanent memory issues. The other has a small tumor being monitored with yearly scans and no symptoms. Even inside the same settlement program, these two cases would likely land in very different tiers, because the money follows the injury — not just the diagnosis.

Why Are Women Filing Depo-Provera Lawsuits?

Women are filing because they say Pfizer knew about a link between Depo-Provera and meningioma brain tumors and didn’t update the U.S. warning label — even though Canada and the European Union added that warning years earlier. The FDA didn’t approve a U.S. label change until December 2025. (See the FDA label revision and related reporting).

The legal theory behind these cases is called failure to warn. Drug makers have a duty to tell patients about risks they know about. If a company hides or downplays a known risk, and someone gets hurt because they never got the warning, that person may have a claim — even if the drug itself was properly made. Depo-Provera Lawsuit Timeline: 2024–2026

Court filings lay out the allegations in more specific terms. Plaintiffs claim Pfizer knew about the meningioma risk, didn’t adequately study or monitor it, kept marketing the shot as safe for long-term use, downplayed the risk in U.S. promotional materials even after adding the warning in Canada and Europe, and pointed to the FDA as the reason it hadn’t updated the U.S. label. Pfizer disputes these characterizations, and none of them have been proven in court.

Here’s what makes this case more interesting than a typical failure-to-warn claim. Pfizer reportedly asked the FDA to add a meningioma warning to the U.S. label back in early 2024. The FDA didn’t approve it right away. Pfizer’s lawyers have leaned on that delay as part of a federal preemption defense — arguing they legally couldn’t have added a warning the FDA hadn’t cleared yet. Then, in December 2025, the FDA did approve the warning. That approval undercuts the “we legally couldn’t” argument, since it shows the change was possible all along — the company just hadn’t gotten it through yet.

One more thing worth knowing: this settlement came together unusually fast for a case this size. Most large pharmaceutical mass torts only settle after years of test trials, called bellwether trials, that show both sides how a jury is likely to rule. Here, Pfizer reached an agreement in principle before a single bellwether trial happened — right after the 2024 BMJ study and the FDA’s December 2025 label change both landed. That timing suggests those two developments put real pressure on the company to resolve the claims early.

The science behind the lawsuits comes largely from a 2024 study published in The BMJ. Researchers found that women who used Depo-Provera for more than a year had roughly a 5.6 times higher risk of developing a meningioma compared to women who never used it.

Court filings in the case also show usage of Depo-Provera skews heavily by race and ethnicity — with reported rates of around 27% among Hispanic women and 41% among Black women who’ve used hormonal birth control, compared to roughly 20% among White women and 7% among Asian women. That’s not a side note. It shapes who this litigation actually affects most.

Here’s what this looks like in practice. Picture a woman who used Depo-Provera from 2015 to 2020, then developed vision problems and headaches by 2023. A woman using the identical drug in Canada during those same years would have seen a meningioma warning printed on her package insert since 2020 — the label was updated there years earlier. The U.S. version of that same box said nothing about brain tumors until December 2025. That gap between what Canadian and European patients were told and what American patients were told is the core of what plaintiffs say Pfizer should have fixed sooner.

Depo-Provera Lawsuit Timeline: 2024–2026

The first Depo-Provera lawsuit was filed in October 2024. Cases were consolidated into MDL No. 3140 in early 2025. Pfizer signed a Master Settlement Agreement in July 2026 covering an estimated 80% of pending claims — but individual payouts likely won’t start until 2027.

A quick honesty note: you’ll find slightly different numbers on different sites for exactly how many cases are pending right now — some report around 5,800, others closer to 6,400. You’ll also see different dates listed for the next major court hearing. That’s not a sign that someone’s making things up. The MDL court docket updates weekly, and different firms pull their numbers on different days. Treat any specific case count you read — including the ones in this article — as a snapshot from a particular date, not a fixed fact.

Two more things worth knowing about where things stand. First, this settlement framework only covers cases filed in the federal MDL. Depo-Provera lawsuits filed separately in state courts — including pending cases in New York, Delaware, and New Mexico — aren’t part of it and are moving forward on their own track. Second, a global settlement like this one typically only funds once a certain share of eligible plaintiffs formally agree to participate. That participation threshold is part of why the full terms haven’t been finalized yet — the deal isn’t just about the dollar amount, it’s also about how many people opt in.

The presiding judge has said the settlement terms will be explained at a town hall meeting once they’re ready, rather than released piecemeal. And behind the scenes, a third-party reviewer has been checking MDL complaints for completeness since June 2025 — meaning a chunk of the paperwork groundwork is already done for cases already on file.

Who May Qualify for a Depo Shot Settlement?

You may qualify if you used Depo-Provera, Depo-SubQ Provera 104, or an authorized generic for roughly a year or more, and you were later diagnosed with a meningioma. Benign tumors generally still qualify — the claim is about the missing warning, not the tumor type.

Most attorneys screening cases look for two core things: documented use of the product, and a confirmed diagnosis that came after you started using it. Beyond that, stronger cases usually have clear medical records, some form of treatment or monitoring, and a plausible timeline connecting the two.

Most meningiomas are benign, meaning noncancerous. But benign doesn’t mean harmless — a tumor’s size and location still matter, and a small minority, roughly 10% to 15%, can become malignant over time. Either way, a benign diagnosis doesn’t disqualify you.

One area worth addressing directly: can you sue Depo-Provera for infertility or PCOS? The current settlement is built specifically around meningioma diagnoses. Claims based only on infertility or polycystic ovary syndrome (PCOS) aren’t part of this settlement track. They face a much higher burden of proof, because a delay in fertility after stopping Depo-Provera has long been a disclosed, known effect — not a newly discovered risk the way meningioma is. If you believe Depo-Provera contributed to infertility or a PCOS-related issue, a lawyer can tell you whether you have a separate, independent claim. Just don’t expect it to fall under this settlement. It’s also worth knowing that published research on fertility after stopping hormonal birth control, including Depo-Provera, generally shows fertility returning over time for most women — which is part of why infertility claims face a tougher road than meningioma claims in this litigation.

Here’s a quick way to think about the “duration” factor. Compare two women: one used Depo-Provera for eight months before switching to a different method, and the other used it continuously for four years. The four-year user has a stronger case on duration alone, since the research linking Depo-Provera to meningioma risk is strongest for use beyond a year. That doesn’t mean eight months automatically disqualifies someone — it just means the rest of that case, especially the medical documentation, needs to carry more of the weight.

What Factors Affect Depo Shot Settlements?

The biggest factors are how severe the meningioma is, whether you needed surgery or radiation, how long you used Depo-Provera, and how well-documented your medical records are. Two women with the same diagnosis can receive very different settlement amounts if their treatment and evidence differ.

• Length of use — longer exposure generally supports a stronger claim
• Treatment required — ongoing monitoring versus surgery versus radiation changes the injury’s severity. A tumor removed through open brain surgery (a craniotomy) is typically valued differently than one treated with a less invasive option like stereotactic radiosurgery, and a tumor that comes back after treatment tends to increase a claim’s value further
• Lost income — time away from work or a reduced ability to work factors into damages
• Permanent effects — seizures, memory loss, or vision and hearing changes tend to increase value
• Documentation strength — clear, consistent medical records connecting use to diagnosis matter more than almost anything else on this list

Lost income looks different from case to case, too. A woman who worked as an accountant and lost eight months of income to surgery recovery and cognitive rehab has a very different wage-loss claim than a woman who took two weeks off for a monitoring scan and went back to work symptom-free. Both may have valid claims — they just won’t be valued the same way.

Symptoms and Side Effects to Watch For

Common meningioma symptoms linked to Depo-Provera lawsuits include persistent headaches, vision or hearing changes, seizures, memory problems, and numbness or weakness. One symptom alone doesn’t confirm a tumor — but worsening symptoms after long-term Depo-Provera use are worth raising with a doctor.

If you’ve used Depo-Provera for a year or more and you’ve noticed headaches that keep getting worse, vision that seems off, ringing in your ears, or moments of confusion that don’t feel like you, don’t try to self-diagnose from a search engine. This article can’t tell you whether what you’re feeling is a meningioma. A doctor and an MRI can.

Is Depo-Provera in a Class Action Lawsuit?

No — Depo-Provera lawsuits are not a class action. They’re handled as a multidistrict litigation (MDL), which groups similar cases together for efficiency but still pays each person based on their own injury. In a class action, everyone typically gets a similar, smaller payout regardless of severity.

This distinction is good news if your injury is serious. An MDL structure means a woman who needed brain surgery isn’t stuck splitting an equal share with someone who had a small, monitored tumor and no symptoms.

Benefits of Hiring a Depo-Provera Lawyer

A Depo-Provera lawyer handles records collection, tracks your state’s statute of limitations, connects your case to the right medical experts, and negotiates with Pfizer on your behalf. Given how complex mass tort procedure is, self-filing this type of claim isn’t practical for most people.

A good attorney does a few things you can’t easily do alone: they know exactly what documentation a claims administrator will expect, they track deadlines that vary by state, and they have relationships with medical experts who can testify that your specific case fits the litigation’s causation theory. Nearly all attorneys handling these cases work on contingency, meaning you pay nothing upfront and they only get paid if you recover money.

When you’re comparing options, look past just name recognition. Ask how many mass tort or pharmaceutical injury cases the firm has actually handled, not just personal injury cases in general. Several national firms — including Morgan & Morgan, along with numerous firms that focus specifically on pharmaceutical mass torts — are actively signing new Depo-Provera clients right now. Talking to more than one before you sign a retainer is normal and won’t hurt your case.

Here’s a small example of why experience matters. An attorney who’s handled dozens of these claims knows a pathology report alone usually isn’t enough — claims administrators typically also want imaging timestamps and a documented injection schedule. Someone filing without that guidance might not find out their claim needs those extra records until it’s already been kicked back for being incomplete, costing weeks they may not have.

Statute of Limitations by State

The statute of limitations for Depo-Provera claims typically runs 2–3 years from diagnosis, but some states allow as little as 1 year. The settlement agreement does not pause these deadlines — waiting for official terms to be released could cost you your right to file.

These are general reference points, not legal advice for your specific case. Deadlines shift depending on your state’s rules and the facts of your situation, so confirm your exact deadline with a licensed attorney in that state.

Many states use something called the discovery rule. Instead of the clock starting on your last Depo-Provera injection, it often starts on the date you knew, or reasonably should have known, that your tumor might be connected to the drug. That’s why your diagnosis date usually matters more than your last shot date.

Here’s why that distinction matters in practice. Say a woman had her last Depo-Provera injection in 2019 but wasn’t diagnosed with a meningioma until 2025. In a state that applies the discovery rule and starts the clock at diagnosis, she likely still has time to file. In a state that counts strictly from her last use, she may have already missed her window. That gap is exactly why guessing at your own deadline is risky, and why it’s worth getting a straight answer from an attorney in your state instead of assuming either way.

Get Help Seeking Depo-Provera Settlements

If you used Depo-Provera and were later diagnosed with a meningioma, the most useful next step is a free case review with an attorney who handles this specific litigation. They can tell you, based on your actual records, whether you fit the current eligibility criteria and how much time you have left to file in your state.

Nothing about a pending settlement changes that timeline for you personally. The safest move is to get your records reviewed now, not after the compensation grid becomes public.

Conclusion

The Depo-Provera lawsuit is real, and it’s moved further than most people realize — from early filings in 2024 to a signed Master Settlement Agreement in July 2026. What hasn’t happened yet is the part most people actually want to know: the confirmed payout amount. That’s still coming.

Don’t let a headline about a settlement talk you out of acting now. Your state’s filing deadline doesn’t wait for the compensation grid to go public, and records get harder to track down the longer you wait. If you used Depo-Provera and were later diagnosed with a meningioma, a free case review with a licensed attorney is the fastest way to find out exactly where you stand.